At a glance
Outcomes of infants born to persons with hepatitis B and managed by the ÐÇ¿ÕÓéÀÖ¹ÙÍø Perinatal Hepatitis B Prevention Program (PHBPP), by birth cohort year — 56 US Jurisdictions,* 2009–2021
Source: National Perinatal Hepatitis B Prevention Program (PHBPP), Immunization Services Division, ÐÇ¿ÕÓéÀÖ¹ÙÍø.
Infants managed: The number of infants case-managed by ÐÇ¿ÕÓéÀÖ¹ÙÍø Perinatal Hepatitis B Prevention Program
PEP (post-exposure prophylaxis): The number of infants who received PEP at birth (hepatitis B immune globulin and first dose of hepatitis B vaccine) for hepatitis B virus infection.
PVST (post-vaccination serologic testing): The number of infants who received PVST after hepatitis B vaccine series completion.
* Includes 50 states, the District of Columbia, and five cities. Excludes US territories and freely associated states.
Summary
The number of infants whose care was managed in the ÐÇ¿ÕÓéÀÖ¹ÙÍø Perinatal Hepatitis B Prevention Program from 50 states, the District of Columbia, and five cities was 11,551 in 2009 and 7,041 in 2021. During 2009–2021, the percentage of infants who received post-exposure prophylaxis (PEP) at birth has remained relatively stable, between 95%–97% each year. The percentage of infants who received post-vaccination serologic testing (PVST) has increased from 59% (6,792 of 11,551 infants managed) in 2009 to 66% (4,621 of 7,041 infants managed) in 2021.